Electra Therapeutics, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Electra Therapeutics adopted an amended and restated certificate of incorporation effective September 21, 2026. Key changes: authorized 910M total shares (900M common, 10M preferred); implemented staggered 3-class board with 66⅔% supermajority required for director removal and bylaw amendments; established Delaware Chancery Court as exclusive forum for derivative and internal-affairs claims, and federal court for Securities Act claims. No equity issuance, financing, or business transaction disclosed.
Why this rating
Corporate governance restructuring; routine for pre-IPO company preparing capital structure. No cash impact, revenue effect, or business change disclosed. Purely administrative.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.